Although we found subtle changes to some key factors, including leptin and glucagon levels in the blood, the study did not reveal strong evidence for heightened risk of metabolic disease or a propensity for weight gain, or any strong new candidates to serve as biomarkers. The gene discussed is GCG; the disease is metabolic disease.